Anti-CD20 treatment to prevent antibody formation in hFVIII protein replacement therapy.

Abstract

<p>BL/6-129/sv-HA and BALB/c-HA mice were treated with αCD20 antibody as outlined in Fig. 1A (indicated with large arrows) followed by 4 weeks of hFVIII challenge (indicated by small arrows) beginning at 4 weeks after the second αCD20 administration. Mice were treated with hFVIII twice more following the same schedule. Antibody formation against HFVIIII was measured by Bethesda assay (<b>A</b>) and anti-hFVIII IgG1 ELISA (<b>B</b>) two weeks after each 4-week challenge. Control mice did not receive αCD20. Gray triangles represent B cell recovery. Data are averages ±<u>SD</u> for n = 3–5/group.</p